224 Results for "

Drug discovery

" in MedChemExpress (MCE) Product Catalog:
Products (224)

224 Results for "Drug discovery" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-124757
CAS No.: 932359-76-7
Purity:  99.87%
Target:  

Proteasome Mitosis

Research Areas:  

Cancer

FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158059
Purity:  99.60%
Target:  

Hedgehog

Research Areas:  

Cancer

DS-1-38 is an EYA1 antagonist that blocks Sonic Hedgehog (SHH) signaling. EYA1 is a haloacid dehalogenase phosphatase and transcription factor that regulates tumorigenesis and proliferation in SHH medulloblastoma (SHH-MB) .
loading...
    loading...
Cat. No.: HY-175510
CAS No.: 3114105-24-4
Target:  

TREM receptor

Research Areas:  

Neurological Disease

TREM2 agonist-5 is the microglial lipid-sensing receptor (TREM2) agonist with a Kd of 71.36 μM. TREM2 agonist-5 is a racemic structural analog of the TREM2 agonist VG-3927 and exhibits superior microglial phagocytosis and activates TREM2 signaling in HEK293-hTREM2/DAP12 cells. TREM2 agonist-5 displays a superior in vitro pharmacokinetic profile to VG-3927. TREM2 agonist-5 can used for the study of Alzheimer’s disease .
loading...
    loading...
Cat. No.: HY-177512
CAS No.: 3098173-17-9
Target:  

FLAP

Research Areas:  

Cancer

MSC778 is an effective and orally active flap endonuclease 1 (FEN1) inhibitor with an IC50 of 3 nM and a KD of 2.9 nM. MSC778 exhibits 145-fold, 516-fold, and 65-fold selectivity over EXO1, GEN1, and XPG, respectively. MSC778 selectively kills BRCA2-deficient cells and potentiates the activity of Niraparib (HY-10619) to induce tumor stasis in a BRCA2 KO DLD-1 mouse xenograft. MSC778 can be used in the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-123297
CAS No.: 1236109-67-3
Purity:  99.90%
Research Areas:  

Metabolic Disease

TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .
loading...
    loading...
Cat. No.: HY-W800659
CAS No.: 29248-48-4
Target:  

ADC Linkers

Research Areas:  

Others

Boc-Gly-Gly-NHS ester can be used to selectively attach small molecules to specific amino acid residues on proteins, creating conjugates that can be used for a variety of applications in drug discovery and diagnostic assays.
loading...
    loading...
Cat. No.: HY-124081
CAS No.: 107743-37-3
Purity:  ≥99.0%
Target:  

Apoptosis

Research Areas:  

Metabolic Disease

N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development .
loading...
    loading...
Cat. No.: HY-W190956
CAS No.: 2172820-12-9
Target:  

Others

Research Areas:  

Cancer

(S,R,S)-AHPC-PEG4-acid is a synthetic PROTAC ligand that binds the E3 ligase ligand to the PEG4 arm, thereby enhancing PROTAC drug research and discovery .
loading...
    loading...
Cat. No.: HY-175845
CAS No.: 2787582-78-7
Research Areas:  

Cancer

Scr-IN-2 is an effective c-Scr inhibitor with an IC50 of 302 nM. Scr-IN-2 exhibits nanomolar-level anti-breast cancer activity. Scr-IN-2 increases the level of ROS in cells, induces mitochondrial damage, G1 phase arrest, and apoptosis. Scr-IN-2 can be used in the research of breast cancer .
loading...
    loading...
Cat. No.: HY-115527
CAS No.: 902891-37-6
Target:  

SHP2

Research Areas:  

Cancer

SHP244 is a conformational inhibitor targeting the "latch allosteric site" (site 2) of the SHP2 protein with an IC50 value for SHP2 WT of 60 μM. SHP244 has no significant effect on the level of p-ERK alone. SHP244 combined with RMC-4550 (HY-116009) ("tunnel site" site 1 inhibitor) can reduce p-ERK and inhibit the rebound of p-ERK, thereby reducing drug resistance. SHP244 can be used to study drug resistance in FGFR-driven cancers .
loading...
    loading...
Cat. No.: HY-153756
CAS No.: 749212-56-4
Purity:  ≥95.0%
Target:  

Prion Protein

Research Areas:  

Infection

GFP16 is a low affinity antiprion compound. GFP16 can be used for research of antiprion drug discovery .
loading...
    loading...
Cat. No.: HY-178441
PKM2-IN-11 is a PKM2 inhibitor (IC50 = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-158861
CAS No.: 2933215-86-0
Purity:  98.5%
Synonyms: G1-nPr-C14E
Target:  

Liposome

Research Areas:  

Others

C3-K2-E14 is a multi-ionizable amino-lipid featuring a central tertiary amine with two identical branches and an n-propyl group. Each branch features a propanamide linking to a branched amine, each with two C14 arms and a hydroxyl. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.
loading...
    loading...
Cat. No.: HY-P2435
CAS No.: 863975-32-0
Target:  

Peptides

Research Areas:  

Others

Bz-Nle-Lys-Arg-Arg-AMC can be used for protease activity assay. In 0.1mL Tris-HCl buffer (50 mM, pH 7.8), Bz-Nle-Lys-Arg-Arg-AMC was hydrolyzed, and the release rate of AMC was observed .
loading...
    loading...
Cat. No.: HY-178283
CAS No.: 3062177-59-4
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-177 is a potent EGFR inhibitor with IC50s of 0.32, 1.04, 0.65, 0.67, 0.48, 0.55 and 0.38 nM against EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S, EGFR D746-750, EGFR D746-750/C797S, EGFR D770_N77linsNPG, and EGFR WT. EGFR-IN-177 inhibits lung cancer proliferation and EGFR phosphorylation. EGFR-IN-177 can be used for the study of cancers such as non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-179377
Target:  

HSP Tau Protein

Research Areas:  

Neurological Disease

Aha1/Hsp90-IN-2 is a selective inhibitor of the Hsp90/Aha1 interaction, with its IC50 being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-P10220
CAS No.: 2914099-35-5
Research Areas:  

Cancer

NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium ( 68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
loading...
    loading...
Cat. No.: HY-W017393
CAS No.: 2362-62-1
Synonyms: 4-Methylbenzenecarbothioamide; 4-Methylbenzenethioamide
Target:  

Drug Intermediate

Research Areas:  

Others

thio-p-Toluamide is a cyclic thioamide building block used in drug discovery chemistry.
loading...
    loading...
Cat. No.: HY-123758
CAS No.: 2138461-99-9
XDM-CBP is a CBP/p300 inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .
loading...
    loading...
Cat. No.: HY-124317
CAS No.: 1621585-17-8
Target:  

Fluorescent Dye

Research Areas:  

Others

PF-06649283 is a drug with potential intracellular activity. The effects of PF-06649283 may be affected by factors such as cellular metabolism, protein-protein interactions, post-translational modifications, and asymmetric intracellular localization. The potency of PF-06649283 at the cellular level may show different activity compared to the recombinant enzyme, and this difference needs to be considered in the drug discovery process. Increased intracellular potency of PF-06649283 may be critical for the development of this drug as a probe or drug .
loading...
    loading...